Leone Melissa, Dillon L Rad
Apria Healthcare.
J Infus Nurs. 2008 Mar-Apr;31(2):84-91. doi: 10.1097/01.NAN.0000313655.65410.4e.
Intravenous catheter outcomes are a prominent topic for healthcare providers whose patients receive intravenous medications. There are thousands of products being marketed today claiming to improve catheter outcomes, thus improving overall patient outcomes and reducing provider costs associated with catheter infections and replacement. Catheter-related bloodstream infections (CR-BSIs) cost hospitals between $5000 and $34,000 per infection, and 12% to 25% of bloodstream infections are attributable to patient mortality. Products that claim to prevent CR-BSIs and subsequently reduce the number of bloodstream infections are a multimillion-dollar industry.
对于为患者提供静脉注射药物的医疗服务提供者而言，静脉导管的使用效果是一个备受关注的话题。如今，市场上有数千种产品宣称可改善导管使用效果，从而提升患者整体治疗效果，并降低与导管感染及更换相关的医疗服务提供者成本。与导管相关的血流感染（CR-BSIs）每次感染给医院造成的成本在5000美元至34000美元之间，且12%至25%的血流感染可归因于患者死亡。声称可预防CR-BSIs并进而减少血流感染数量的产品构成了一个价值数百万美元的产业。
